At Dana-Farber Cancer Institute (DFCI), the CIMAC functions within a local hub of translational immuno-oncology activity that supports dedicated translational biomarker laboratories to provide expertise in the analysis of immune correlatives in the service of immuno-oncology trials. This group has access to Dana Farber’s exceptional sample tracking system and pathology services to support advanced computational methods and enable large-scale integrative data analysis. In addition, cutting-edge technology and approaches developed at the institution allows for the CIMAC to extract useful biologic information from patient material using high-throughput DNA/RNA sequencing and highly multiplexed biological assays. This CIMAC works primarily with the Experimental Therapeutics Clinical Trials Network (ETCTN) and has leveraged experience gained from existing collaborations with NCI Clinical Trials Network and Consortia to contribute to the success of the system on a variety of levels.
Catherine J. Wu, MD, is a professor of medicine at Harvard Medical School as well as an associate physician of medical oncology at Dana-Farber Cancer Institute and Brigham and Women’s Hospital. Her research focuses on how best to effectively mount human immune responses to recognize and eradicate cancer, with dedicated effort on the discovery and targeting of tumor antigens. A longstanding theme of her studies has been how best to launch immunotherapeutic efforts in a personalized fashion, initially through studies in the area of hematopoietic stem cell transplantation (HSCT), together with whole tumor cell vaccination, and more recently through the implementation of personal neoantigen-targeting cancer vaccines.
Stephen Hodi, MD, is the Director of the Melanoma Center and the Center for Immuno-Oncology at Dana-Farber/Brigham and Women’s Cancer Center and Professor of Medicine at Harvard Medical School. His research focuses on gene therapy, the development of immune therapies, and first into human studies for malignant melanoma. Dr. Hodi is most well known for the clinical development of checkpoint inhibitors.